32407-67-3

Usage

InChI:InChI=1/C12H16O5/c1-4-17-12(14)11(13)8-5-6-9(15-2)10(7-8)16-3/h5-7,11,13H,4H2,1-3H3

Upstream product

• 64-17-5 ethanol 
• 40233-98-5 3,4-dimethoxyphenylglyoxylic acid ethyl ester 
• 91-16-7 1,2-dimethoxybenzene 

Downstream Products

• 13627-17-3 5-(3,4-dimethoxy-phenyl)-3-methyl-2-methylimino-oxazolidin-4-one 
• 29229-86-5 ethyl fluoro-[3,4-dimethoxyphenyl]acetate 
• 13627-12-8 5-(3,4-dimethoxy-phenyl)-2-dimethylamino-oxazol-4-one 
• 3152-27-0 bromo 3,4-dimethoxyphenylacetic acid ethyl ester 
• 131030-55-2 carboxymethylsulfanyl-(3,4-dimethoxy-phenyl)-acetic acid ethyl ester 
• 911047-47-7 (diethoxyphosphoryl)-3,4-dimethoxyphenylacetic acid ethyl ester 
• 41024-41-3 chloro-(3,4-dimethoxy-phenyl)-acetic acid ethyl ester 
• 13443-54-4 3,4-dimethoxyphenylglycolic acid 

Relevant academic research and scientific papers

NEGATIVE ALLOSTERIC MODULATION OF GLUN3-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS

Disclosed are negative allosteric modulators of GluN3-containing NMDA receptors. In general, these compounds are highly selective for GluN3 (such as GluN3A and/or GluN3B) over GluN1 and/or GluN2. They can function as non-competitive antagonists with activity that is independent of membrane potential, glycine concentration, and extracellular pH. Also disclosed are pharmaceutical formulations of the negative allosteric modulators. These compounds can be used to enhance synaptic function and/or treating a neurological condition or disorder. Exemplary neurological conditions or disorders include, but are not limited to, major mental disorders, conditions that involve basal ganglia or altered dopamine, substance abuse/addiction or predisposition to substance abuse/addiction, pain disorders, developmental delay or situations with impaired learning, memory, and/or cognition, acute neuronal or glial injuries, and circuit disorders.

Reliable and versatile synthesis of 2-aryl-substituted cinnamic acid esters

2-Aryl-substituted phosphono acetates can be readily synthesized by a four-step sequence from the respective arenes. Succeeding Horner-Wadsworth- Emmons olefinations provide stereoselectively the 2-aryl cinnamic acid esters even when sensitive moieties are involved. Georg Thieme Verlag Stuttgart.

Sulfur-containing heterocyclic compounds useful for the treatment of osteoporosis, and their production

The present invention provides a sulfur-containing heterocyclic compound of the formula (I) STR1 wherein ring A is a benzene ring which may be substituted; R is a hydrogen atom or a hydrocarbon group which may be substituted; B is a carboxyl group which may be esterified or amidated; X is --CH(OH)-- or --CO--; k is 0 or 1; and k' is 0, 1 or 2 or a pharmaceutically acceptable salt thereof. Also, it provides a process for producing the compound (I) or a salt thereof and a pharmaceutical preparation for use in the treatment of osteoporosis comprising the compound (I) or salt thereof. The compounds (I) and salts thereof show excellent bone resorption inhibitory activity.